Capivasertib Plus Fulvestrant Improves PFS in Those With Advanced HR+/HER2- Breast CancerDecember 9th 2022
Results from the phase 3 CAPItello-291 clinical trial show that the combination doubled the median progression-free survival compared with the placebo in patients with HR-positive, HER2-negative advanced breast cancer.
ALP Plus Fulvestrant Delivers Solid Results for PIK3CA-Mutated, HR+/HER2- Breast CancerDecember 9th 2022
BYLieve clinical trial data indicate long-term and very-long-term data disease control was observed in 25.6% and 16.5% of patients, respectively, with PFS at 24.8 and 29.4 months in patients with HR-positive, HER2-negative advanced breast cancer.
Metformin Meets Primary Endpoint in Study of ALP-Induced Hyperglycemia in Advanced Breast CancerDecember 8th 2022
Efficacy and safety profile in combination with alpelisib is comparable to that reported in the BYLieve and SOLAR-1 clinical trials, according to a poster presentation at the San Antonio Breast Cancer Symposium.
Trastuzumab Deruxtecan Bests Chemotherapy-Based Regimens in Those Previously Treated With T-DM1December 8th 2022
DESTINY-Breast02 clinical trial results show trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in progression-free and overall survival.
Interim Analysis Updates Adjuvant Abemaciclib Plus Endocrine Therapy StudyDecember 7th 2022
Phase 3 monarchE trial assesses distant relapse free-survival, invasive disease-free survival, and overall survival for the treatment of HR-positive/HER2-negative-, node-positive, high-risk early breast cancer.